The expert panel unanimously concluded that the intended use of Bonolive as food ingredient is GRAS. The dossier also endorses the use of the ingredient at the clinical dose per serving in a wide variety of food categories.
The scientific publications on the ingredient comprise two human efficacy studies, its pharmacokinetics, five preclinicals and the mechanism of action, according to a release by Ferrer HealthTech. A recently completed OECD compliant safety study has underscored the excellent safety profile of Bonolive. These results have been published in the International Journal of Toxicology (Vol. 35, pp. 208-221) and the poster was presented at the Annual Meeting of the Society of Toxicologists (March 2016).
The review of Bonolive was commissioned and co-funded by Spain-based Ferrer HealthTech and Netherlands-based BioActor.